Amgen Asks High Court To Hear Landmark Case

Law360, New York (March 22, 2007, 12:00 AM EDT) -- Seeking a high profile review of the 12-year old Markman rule, biotech company Amgen Inc. asked the U.S. Supreme Court on Thursday to decide whether a federal appeals court should give deference to findings made by a trial court during claim construction.

If accepted, Amgen’s case would allow the Supreme Court to signal to the U.S. Court of Appeals for the Federal Circuit whether its decision-making is on track with the law—not to mention revive Amgen’s patent infringement case against French rival Sanofi-Aventis.

Amgen’s petition asks...
To view the full article, register now.